Sunho Biologics (HKSE:02898) Other Current Assets: HK$ Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02898 Sunho Biologics Inc HKSE:02898
11 GF Score
Price HK$6.39
! 1 Warning Sign
View Full Analysis

What is Sunho Biologics Other Current Assets?

Sunho Biologics HKSE:02898 11 Other Current Assets is HK$ Mil as of Jun. 2023. GuruFocus rates HKSE:02898 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Sunho Biologics's other current assets for the quarter that ended in Jun. 2023 was HK$ Mil.

Sunho Biologics's quarterly other current assets increased from Mar. 2022 (HK$ Mil) to Mar. 2023 (HK$12.10 Mil) but then declined from Mar. 2023 (HK$12.10 Mil) to Jun. 2023 (HK$Mil).

Sunho Biologics's annual other current assets increased from Dec. 2022 (HK$12.27 Mil) to Dec. 2023 (HK$16.80 Mil) increased from Dec. 2023 (HK$16.80 Mil) to Dec. 2024 (HK$19.26 Mil).


Sunho Biologics Other Current Assets Related Terms


Sunho Biologics Other Current Assets Historical Data

* Premium members only.

The historical data trend for Sunho Biologics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunho Biologics Other Current Assets Chart

Sunho Biologics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Other Current Assets
4.19 12.27 16.80 19.26

Sunho Biologics Quarterly Data
Mar22 Mar23 Jun23
Other Current Assets - 12.10 -
HKSE:02898
11GF Score
Sunho Biologics Inc HKSE:02898
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunho Biologics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of HK$ Mil mean?
Sunho Biologics (HKSE:02898) has a Other Current Assets of HK$ Mil as of Jun. 2023. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sunho Biologics.
Is Sunho Biologics' Other Current Assets too high?
Sunho Biologics' current Other Current Assets is HK$ Mil. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' Other Current Assets compare to VRTX and REGN?
Sunho Biologics' Other Current Assets of HK$ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sunho Biologics. Sunho Biologics's current Other Current Assets is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current Other Current Assets of HK$ Mil. The current Other Current Assets is HK$ Mil. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current Other Current Assets is HK$ Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunho Biologics Business Description

Address No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score

Get the complete analysis for HKSE:02898

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.39
Price